Abstract: Late-phase tech transfer is not about reinventing a process.

Abstract: As antibody-drug conjugates (ADCs) grow more complex, comprehensive analytical services are becoming central to successful development from discovery through commercialization.

Abstract: This webinar highlights Catalent’s GPEx® Lightning platform and transient expression capabilities, demonstrating how sponsors can accelerate biologics development while reducing time to critical decision points.

Abstract: Successful ADC development depends on an analytical strategy that addresses molecular complexity from the earliest stages and evolves through commercialization.

Abstract: Cell and gene therapy supply chains are uniquely complex, requiring precise coordination, regulatory compliance, and robust logistics to ensure timely delivery of life-saving treatments.

Abstract: Choosing between modular and fully integrated manufacturing platforms is a critical decision for cell therapy developers, impacting scalability, cost efficiency, and commercial viability.

Abstract: Process characterization is essential for cell therapy programs, ensuring consistent, safe, and effective products that meet regulatory standards.

Abstract: Cell therapies have complex manufacturing needs since the final drug product is viable cells comprising thousands of proteins, lipids and carbohydrates that can change with every manipulation step.

Abstract: Open steps in cell therapy manufacturing expose products to contamination risk, operational complexity, and scalability limitations.

Abstract: Cell therapy manufacturing demands rigorous quality control, as living cell products cannot be terminally sterilized and are often produced in small batches.